(Cervical Cancer) Is Sintilimab Plus Anlotinib Effective? Phase 2 Trial Results
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- February 22, 2022
- 2 min read
On February 22, 2022, Qin Xu and colleagues from Fujian Medical University Cancer Hospital published results in the Journal of Clinical Oncology from a Phase 2 clinical trial evaluating the efficacy and safety of sintilimab (anti-PD-1 antibody) plus anlotinib (tyrosine kinase inhibitor) in previously treated, PD-L1-positive, recurrent/metastatic cervical cancer patients.
Trial Design:
This Phase 2 trial administered sintilimab (200 mg on Day 1) plus anlotinib (10 mg once daily, Days 1–14) on a 3-week cycle to previously treated, PD-L1-positive, recurrent/metastatic cervical cancer patients. The primary endpoint was objective response rate (ORR); secondary endpoints were PFS, OS, and disease control rate (DCR).
Results (N=42 enrolled; N=39 evaluable):
- Primary endpoint ORR: 59.0%
- Disease control rate (DCR): 94.9%
- Median PFS: 9.4 months
- Median OS: Not reached
Safety:
Overall adverse event rate: 85.8%. Most common adverse events: hypothyroidism 33.3%, AST elevation 21.4%, hypertension 19.0%.
Conclusion: Based on the Phase 2 trial results, Qin Xu and colleagues concluded that sintilimab plus anlotinib demonstrated favorable anti-tumor activity with an acceptable tolerability profile in previously treated, PD-L1-positive, recurrent/metastatic cervical cancer patients.
Source: https://ascopubs.org/doi/full/10.1200/JCO.21.02091
Cervical Cancer | Immunotherapy | Sintilimab | Anlotinib
-
Clinical Trial Medications
-
Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4